ifosfamide has been researched along with Lung Diseases, Interstitial in 1 studies
Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ifosfamide is an active alkylating agent used in the first-line treatment of NSCLC." | 2.71 | Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. ( Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YM | 1 |
| Shih, JF | 1 |
| Lee, CS | 1 |
| Chen, MC | 1 |
| Lin, WC | 1 |
| Tsai, CM | 1 |
| Perng, RP | 1 |
1 trial available for ifosfamide and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2003 |